EANS-Adhoc: Intercell acquires antibody technology platform to further exploit its capabilities to combat infectious diseases

--------------------------------------------------------------------------------
ad-hoc disclosure transmitted by euro adhoc with the aim of a Europe-wide
distribution. The issuer is solely responsible for the content of this
announcement.
--------------------------------------------------------------------------------

Research & Development

06.05.2010

Vienna (Austria), May 6, 2010 - Intercell AG (VSE: ICLL) today
announced that it has signed an agreement with Cytos Biotechnology
Ltd. to acquire Cytos' platform technology for monoclonal antibody
discovery. The technology is based on expression cloning of
monoclonal antibodies from human B-cells and enables the
identification of anti-infective antibodies to prevent and treat
infectious diseases.

Under the agreed terms Intercell will pay EUR 15 million to Cytos.
Intercell will own certain unpartnered monoclonal antibody assets,
including promising pre-clinical anti-infective antibody candidates
discovered by Cytos. The key scientists, who have very successfully
developed the technology at Cytos, will be employed by Intercell. The
antibody technology complements Intercell's technology platforms and
opens novel medically and commercially relevant applications for
Intercell's Antigen Identification Program (AIP®). The AIP® has
delivered promising vaccine candidates against Staphylococcus aureus
(Phase II/III) and Pneumococcus (Phase I) infections, among others,
and has also been the basis for partnerships in the antibody field
with Merck & Co. and Kyowa Hakko Kirin in these indications,
respectively.

In its future antibody discovery activities Intercell will focus on
medically and commercially attractive AIP® derived disease targets
including Group B Streptococcus and bacteria involved in hospital
acquired infections.

"Cytos' outstanding antibody technology complements our innovative
R&D technology platform and enables pipeline progression within our
existing portfolio", stated Gerd Zettlmeissl, Chief Executive Officer
of Intercell.

Wolfgang Renner, CEO of Cytos, commented: "Intercell, as a leading
anti-infective company, is ideally positioned through its Antigen
Identification Program (AIP®), to capture the full value of our
monoclonal antibody discovery platform. We are very glad that our
technology will support Intercell in discovering important new
monoclonal antibodies to combat infectious diseases."

Monoclonal antibodies form one of the fastest growing segments of the
pharmaceutical industry. The global monoclonal antibodies market was
valued at USD 27.4bn in 2008, indicating a Compound Annual Growth
Rate (CAGR) of almost 30% between 2000 and 2008.1

"Antibodies can be extremely effective for the prevention and
treatment of infectious diseases. For example, the increasing rate of
antibiotic resistance among certain types of nosocomial pathogens
makes it extremely difficult to control hospital acquired infectious
diseases in critical situations. Anti-infective antibodies, well
known in the medical arena before the advent of antibiotic
treatments, have experienced a comeback and monoclonal antibody
products are expected to contribute to the control of severe
infections that otherwise might be untreatable in the future",
explained Eszter Nagy, Senior Vice President Research at Intercell.

-------------------------------
1 http://www.marketresearch.com/product/display.asp?productid=2515126

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Intercell AG

Lucia Malfent

Vice President, Global Head Corporate Communications

Tel. +43 1 20620-1303

lmalfent@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Index: ATX Prime, ATX
Börsen: Wien / official market